Intellia Therapeutics, Inc.
NTLA
$9.20
-$0.40-4.17%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -8.32% | -7.86% | -12.94% | -12.21% | -12.79% |
| Total Depreciation and Amortization | 8.83% | 14.58% | 19.25% | 20.31% | 19.95% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 34.29% | 13.32% | 7.91% | -1.30% | -12.81% |
| Change in Net Operating Assets | 62.06% | 122.65% | 118.77% | 82.47% | 38.14% |
| Cash from Operations | 6.97% | 11.47% | 8.74% | -1.42% | -11.74% |
| Capital Expenditure | 68.35% | 58.68% | 61.43% | 42.45% | 20.69% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 99.16% | 856.51% | 128.84% | 194.61% | 1,610.60% |
| Cash from Investing | 121.06% | 500.57% | 118.56% | 176.92% | 1,128.50% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -33.14% | 42.53% | -45.26% | -57.56% | -65.03% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -33.14% | 42.53% | -45.26% | -57.56% | -65.03% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 68.97% | 87.27% | -249.97% | -244.86% | -172.77% |